Published in World Allergy Organ J on March 28, 2014
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract | NCT00619827
Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. World Allergy Organ J (2016) 1.41
Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organ J (2016) 1.40
Effect of Inhalation of Aromatherapy Oil on Patients with Perennial Allergic Rhinitis: A Randomized Controlled Trial. Evid Based Complement Alternat Med (2016) 1.39
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J (2015) 1.03
Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J (2014) 0.86
International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ J (2017) 0.83
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. Clin Mol Allergy (2015) 0.82
The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. Allergy Asthma Clin Immunol (2015) 0.80
Effect of high-dose sublingual immunotherapy on respiratory infections in children allergic to house dust mite. Asia Pac Allergy (2015) 0.80
Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis. Allergy Asthma Clin Immunol (2015) 0.80
Mucosal vaccine delivery: Current state and a pediatric perspective. J Control Release (2016) 0.80
A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy (2015) 0.79
Tolerogenic insulin peptide therapy precipitates type 1 diabetes. J Exp Med (2017) 0.78
"The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis". Clin Transl Allergy (2015) 0.78
A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. Clin Transl Allergy (2014) 0.78
Allergen immunotherapy on the way to product-based evaluation-a WAO statement. World Allergy Organ J (2015) 0.78
Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. Clin Mol Allergy (2017) 0.77
The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clin Mol Allergy (2015) 0.77
Improving the safety of oral immunotherapy for food allergy. Pediatr Allergy Immunol (2015) 0.76
AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy (2015) 0.76
New treatments for allergen immunotherapy. World Allergy Organ J (2014) 0.76
Sublingual Immunotherapy for Asthmatic Children Sensitized to House Dust Mite: A Meta-Analysis. Medicine (Baltimore) (2015) 0.76
Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period. World Allergy Organ J (2017) 0.76
Developing therapies for peanut allergy. Int Arch Allergy Immunol (2014) 0.76
Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol (2016) 0.76
Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center. Patient Prefer Adherence (2017) 0.75
Allergen immunotherapy in asthma; what is new? Asthma Res Pract (2015) 0.75
Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence. Clin Mol Allergy (2017) 0.75
Allergen-specific immunotherapy in pediatric allergic asthma. Asia Pac Allergy (2016) 0.75
Therapeutic interventions in severe asthma. World Allergy Organ J (2016) 0.75
Critical appraisal of Timothy grass pollen extract GRAZAX(®) in the management of allergic rhinitis. Drug Des Devel Ther (2015) 0.75
Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. Clin Transl Allergy (2015) 0.75
Importance of Quality of Life for Adherence to Sublingual Immunotherapy. Biomed Res Int (2016) 0.75
Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy Asthma Clin Immunol (2016) 0.75
Lung-derived innate cytokines: new epigenetic targets of allergen-specific sublingual immunotherapy. Iran J Basic Med Sci (2016) 0.75
Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr (2017) 0.75
How does the efficacy and safety of Oralair(®) compare to other products on the market? Ther Clin Risk Manag (2016) 0.75
Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey. Allergy Asthma Clin Immunol (2016) 0.75
Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose. Clin Transl Allergy (2015) 0.75
Evaluation of a sublingual immunotherapy solution in olive-induced respiratory allergy in Jordan: a retrospective observational study. J Asthma Allergy (2017) 0.75
A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Allergy (2016) 0.75
A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia). Patient Prefer Adherence (2017) 0.75
Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. Front Pediatr (2017) 0.75
Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report. Clin Transl Allergy (2017) 0.75
Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life. Health Qual Life Outcomes (2017) 0.75
Treatment Satisfaction During Sublingual Immunotherapy with a Five-Grass Pollen Tablet for Allergic Rhinoconjunctivitis: A Prospective, Non-Interventional Study. Drugs Real World Outcomes (2017) 0.75
[Costs of allergic diseases and saving potential by allergen-specific immunotherapy : A personal assessment]. HNO (2017) 0.75
Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials. Patient (2017) 0.75
Nanoparticle-allergen complexes for allergen immunotherapy. Int J Nanomedicine (2017) 0.75
Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products. PLoS One (2017) 0.75
Adherence to medication. N Engl J Med (2005) 39.77
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 10.08
Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol (2001) 7.27
Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart. BMJ (1992) 6.75
Clinical guidelines: developing guidelines. BMJ (1999) 6.01
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol (2010) 5.80
Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J (2000) 5.54
House dust mite control measures in the management of asthma: meta-analysis. BMJ (1998) 3.41
Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 3.08
Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (2007) 2.77
Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol (2005) 2.70
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy. J Allergy Clin Immunol (2009) 2.32
Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol (2010) 2.32
SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol (2012) 2.28
Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol (2004) 2.18
Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol (2013) 2.15
Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol (2010) 2.11
Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev (2010) 2.10
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy (2007) 2.10
Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ (2000) 2.06
Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf (2005) 2.05
Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol (2007) 2.02
Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy (2006) 1.97
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol (2013) 1.96
The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy (2008) 1.96
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol (2011) 1.93
Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest (2007) 1.84
Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol (2011) 1.84
The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol (2011) 1.81
Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol (2010) 1.80
Prioritising the respiratory research needs of primary care: the International Primary Care Respiratory Group (IPCRG) e-Delphi exercise. Prim Care Respir J (2012) 1.77
The International Primary Care Respiratory Group (IPCRG) Research Needs Statement 2010. Prim Care Respir J (2010) 1.76
Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy (2007) 1.75
Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy (2010) 1.72
Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med (2004) 1.71
Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy (1986) 1.71
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol (2010) 1.67
Molecular profiles of IgE to Phleum pratense in children with grass pollen allergy: implications for specific immunotherapy. J Allergy Clin Immunol (2011) 1.67
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol (2007) 1.64
Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol (2008) 1.64
House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy (2013) 1.58
Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data. BMJ (2003) 1.58
Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol (2007) 1.57
Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet (1998) 1.56
Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol (2010) 1.55
Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. Pediatr Allergy Immunol (2011) 1.55
Comparison between major histocompatibility complex class II tetramer staining and surface expression of activation markers for the detection of allergen-specific CD4⁺ T cells. Clin Exp Allergy (2011) 1.53
The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy (2011) 1.52
Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents. Pediatr Allergy Immunol (2010) 1.52
A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy (2008) 1.50
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol (2012) 1.49
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine (2001) 1.49
Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression. Clin Exp Allergy (2010) 1.48
Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J (2012) 1.48
Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy (2004) 1.47
The role of allergens in asthma. Am Fam Physician (2007) 1.47
Physician attitudes, opinions, and referral patterns: comparisons of those who have and have not taken an allergy/immunology rotation. Ann Allergy Asthma Immunol (2004) 1.47
Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann Allergy Asthma Immunol (2003) 1.46
Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol (2008) 1.46
Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy (2011) 1.46
Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol (2011) 1.45
Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol (2006) 1.41
Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. Pediatr Allergy Immunol (2008) 1.41
International Primary Care Respiratory Group (IPCRG) Guidelines: management of allergic rhinitis. Prim Care Respir J (2005) 1.38
Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol (2011) 1.37
Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol (2013) 1.36
Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol (2011) 1.36
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy (2009) 1.34
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol (2008) 1.33
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol (2012) 1.29
GA² LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy (2010) 1.28
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol (1997) 1.27
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol (2006) 1.26
Systematic reviews of sublingual immunotherapy (SLIT). Allergy (2011) 1.25
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol (2009) 1.23
Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol (2007) 1.21
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy (2011) 1.20
Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. J Allergy Clin Immunol (1995) 1.19
The safety of immunotherapy during pregnancy. J Allergy Clin Immunol (1978) 1.18
Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy (2011) 1.18
How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area. Allergy (2012) 1.16
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol (2011) 1.15
Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy (2008) 1.14
Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol (2009) 1.13
Immunotherapy for allergic rhinitis. Clin Exp Allergy (2011) 1.13
Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol (2006) 1.11
Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol (2007) 1.11
House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med (2009) 1.10
Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy (1999) 1.10
Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy (2006) 1.09
CSM Update: Desensitising vaccines. Br Med J (Clin Res Ed) (1986) 1.09
Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med (2012) 1.08
International survey on skin patch test procedures, attitudes and interpretation. World Allergy Organ J (2016) 1.09
Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11. J Allergy Clin Immunol Pract (2016) 0.90
Climate Change and Air Pollution: Effects on Respiratory Allergy. Allergy Asthma Immunol Res (2016) 0.85
Allergy training and immunotherapy in Latin America: results of a regional overview. Ann Allergy Asthma Immunol (2013) 0.82
A survey of clinical features of allergic rhinitis in adults. Med Sci Monit (2014) 0.80
The microbiome of the human lower airways: a next generation sequencing perspective. World Allergy Organ J (2015) 0.79
Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J (2016) 0.79
Allergen immunotherapy on the way to product-based evaluation-a WAO statement. World Allergy Organ J (2015) 0.78